Page last updated: 2024-08-24

gemcitabine and defactinib

gemcitabine has been researched along with defactinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abdiannia, M; Acharya, A; Aranha, O; Belle, JI; Bogner, SJ; Boice, N; Breden, M; Brown, A; DeNardo, DG; Gao, F; Hawkins, WG; Herndon, J; Herzog, BH; Lim, KH; Lockhart, AC; McWilliams, R; Pedersen, K; Ratner, L; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A; Yoon, HH; Zhu, M	1

Trials

1 trial(s) available for gemcitabine and defactinib

Article	Year
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 12-15, Volume: 28, Issue:24 Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms	2022

Article

Year

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 12-15, Volume: 28, Issue:24

Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms

2022